CrossPoint Therapeutics

CrossPoint Therapeutics, founded in October 2022, is a biotechnology company focused on developing innovative drugs using its proprietary Stealth Body technology. This technology aims to limit off-target toxicity issues, which are unintended effects on non-target cells, thereby enhancing the safety and efficacy of next-generation antibody therapies. The company operates in the pharmaceutical and biotechnology market, primarily serving patients with refractory diseases—conditions that are resistant to standard treatments. CrossPoint Therapeutics' business model revolves around research and development (R&D) of novel therapeutic options, which are then brought to market either through direct sales or partnerships with larger pharmaceutical companies. Revenue is generated through the commercialization of these therapies, licensing agreements, and potential milestone payments from collaborators. The company is committed to expanding the range of curable diseases and improving the quality of life for patients.

Keywords: Biotechnology, Antibody Therapies, Stealth Body, Drug Development, Refractory Diseases, Off-Target Toxicity, Proprietary Technology, Pharmaceutical, Patient Well-being, Innovation.